Staged Multi-Agent Training (SMAT) for Hip Exoskeletons: Metabolic and Biomechanical Validation of a Simulation-Trained Co-Adaptive Controller

Sicherheitsmeldung mit Schweregrad noch nicht bewertet. Technische Details im Tab „Originaltext“; empfohlene Schritte in der Checkliste.

Originaltext der Quelle (nicht übersetzt) – die deutsche Zusammenfassung findest du im Tab „Kurzfassung".

arXiv:2608.00715v1 Announce Type: cross Abstract: Learning-based controllers can deliver exoskeleton assistance after training entirely in physics-based simulation, yet few controllers that address human-device co-adaptation have been validated on real users by whole-body metabolic measurement, the standard benchmark for assistive walking. Co-adaptation is challenging: as the device alters joint dynamics, the wearer reorganizes neuromuscular coordination, producing a non-stationary learning problem. Staged Multi-Agent Training (SMAT), a four-stage curriculum that progressively trains a musculoskeletal human actor and a bilateral hip exoskeleton actor, was introduced and shown to reduce simulated hip-muscle activation and provide positive assistance on hardware. This article provides the first physiological validation of SMAT. The policy was deployed on a hip exoskeleton and tested with eight healthy adults, with metabolic cost measured by indirect calorimetry across no-exoskeleton, passive, and active conditions. Active assistance lowered net metabolic rate by 19.7% relative to the passive device (p < 0.001). Biomechanical analysis confirmed predominantly positive hip mechanical power across all subjects (positive-power ratio 0.98), and the policy generalized across walking speeds and terrains. Together, these results show that a single simulation-trained SMAT policy, deployed without subject-specific retraining, delivers a significant metabolic benefit on real users while remaining robust beyond the conditions it was trained on.

Vollständiger Originalartikel ↗

• Betroffenheit im eigenen Stack prüfen: Versionen/Komponenten abgleichen.
• Originalquelle / Hersteller-Advisory lesen: https://arxiv.org/abs/2608.00715
• Verfügbaren Patch oder Workaround einspielen und dokumentieren.